CARGO Therapeutics to Participate in the 44th Annual Cowen Healthcare Conference

Rhea-AI Summary

CARGO Therapeutics, Inc. (CRGX) will participate in the 44th Annual Cowen Healthcare Conference to discuss cell therapies for cancer patients. Gina Chapman, the CEO, will join a panel on March 6, 2024, at 9:10 a.m. EST. The webcast will be available on CARGO's website.

SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44^th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a cell therapy corporate panel discussion on Wednesday, March 6, at 9:10 a.m. EST.

A live webcast of the panel discussion will be accessible through the Investors section of CARGO’s website under News & Events. A replay of the webcast will be available after the conclusion of the live presentation for 30 days.

About CARGO

CARGO Therapeutics, Inc. is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. CARGO’s programs, platform technologies, and manufacturing strategy are designed to directly address the limitations of approved cell therapies, including limited durability of effect, safety concerns and unreliable supply. CARGO is currently evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy. CARGO also plans to evaluate CRG-022 in patients at earlier stages of disease, including LBCL and other hematologic malignancies. Beyond its lead program, CARGO is leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic “cargo” designed to enhance CAR T-cell persistence and trafficking to tumor lesions, as well as to help safeguard against tumor resistance and T-cell exhaustion. CARGO’s founders are pioneers and world-class experts in CAR T-cell therapy, and CARGO’s team has significant experience and success developing, manufacturing, launching and commercializing oncology and cell therapy products.

Media Contact:
Maura Gavaghan
maura@redhousecomms.com

Investor Contact:
Laurence Watts
laurence@gilmartinir.com

FAQ

When will CARGO Therapeutics, Inc. participate in the 44th Annual Cowen Healthcare Conference?

CARGO Therapeutics, Inc. will participate in the 44th Annual Cowen Healthcare Conference from March 4-6, 2024.

Who is scheduled to participate in the cell therapy corporate panel discussion?

Gina Chapman, the President and CEO of CARGO Therapeutics, Inc., is scheduled to participate in the cell therapy corporate panel discussion.

Where will the 44th Annual Cowen Healthcare Conference take place?

The 44th Annual Cowen Healthcare Conference will take place in Boston, Massachusetts.

How can investors access the live webcast of the panel discussion?

Investors can access the live webcast of the panel discussion through the Investors section of CARGO's website under News & Events.

Will there be a replay of the webcast available?

Yes, a replay of the webcast will be available after the conclusion of the live presentation for 30 days.